358 related articles for article (PubMed ID: 26769845)
1. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
Chen CS; Li FK; Guo CY; Xiao JC; Hu HT; Cheng HT; Zheng L; Zong DW; Ma JL; Jiang L; Li HL
Oncotarget; 2016 Feb; 7(6):7241-52. PubMed ID: 26769845
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
4. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
5. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
Yang Z; Zou R; Zheng Y; Qiu J; Shen J; Liao Y; Zhang Y; Wang C; Wang Y; Yuan Y; Li K; Zuo D; He W; Liu W; Li B; Yuan Y
Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438
[TBL] [Abstract][Full Text] [Related]
6. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
[TBL] [Abstract][Full Text] [Related]
7. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma.
Carr BI; Bron K; Swanson DP
J Clin Gastroenterol; 2011 Oct; 45(9):e87-91. PubMed ID: 21921843
[TBL] [Abstract][Full Text] [Related]
9. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
[TBL] [Abstract][Full Text] [Related]
10. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization.
Yang L; Zhang XM; Zhou XP; Tang W; Guan YS; Zhai ZH; Dong GL
J Vasc Interv Radiol; 2010 Dec; 21(12):1841-6. PubMed ID: 20980165
[TBL] [Abstract][Full Text] [Related]
11. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
[TBL] [Abstract][Full Text] [Related]
12. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
Yodono H; Matsuo K; Shinohara A
Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
[TBL] [Abstract][Full Text] [Related]
13. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
14. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply.
Paul SB; Gamanagatti SR; Mukund A; Abbas SZ; Acharya SK
Indian J Cancer; 2011; 48(3):339-44. PubMed ID: 21921335
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT.
Chen R; Geschwind JF; Wang Z; Tacher V; Lin M
J Vasc Interv Radiol; 2013 Dec; 24(12):1837-44. PubMed ID: 24094672
[TBL] [Abstract][Full Text] [Related]
17. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome.
Herber S; Biesterfeld S; Franz U; Schneider J; Thies J; Schuchmann M; Düber C; Pitton MB; Otto G
Cardiovasc Intervent Radiol; 2008; 31(4):768-77. PubMed ID: 18196335
[TBL] [Abstract][Full Text] [Related]
18. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
Favelier S; Boulin M; Hamza S; Cercueil JP; Cherblanc V; Lepage C; Hillon P; Chauffert B; Krausé D; Guiu B
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ
BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma.
Jun CH; Ki HS; Lee HK; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
World J Gastroenterol; 2013 Jan; 19(2):284-9. PubMed ID: 23345952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
